Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NUVB |
---|---|---|
09:32 ET | 11173 | 3.17 |
09:34 ET | 3007 | 3.15 |
09:36 ET | 700 | 3.145 |
09:38 ET | 500 | 3.135 |
09:39 ET | 17705 | 3.12 |
09:41 ET | 19779 | 3.095 |
09:43 ET | 4491 | 3.0692 |
09:45 ET | 13778 | 3.06 |
09:48 ET | 3217 | 3.05 |
09:50 ET | 1224 | 3.05 |
09:52 ET | 3200 | 3.055 |
09:54 ET | 20318 | 3.0674 |
09:56 ET | 6365 | 3.065 |
09:57 ET | 20596 | 3.04 |
09:59 ET | 7195 | 3.035 |
10:01 ET | 3986 | 3.045 |
10:03 ET | 8227 | 3.035 |
10:06 ET | 11749 | 3.03 |
10:08 ET | 3446 | 3.015 |
10:10 ET | 18673 | 3.015 |
10:12 ET | 13405 | 3 |
10:14 ET | 1000 | 2.9948 |
10:15 ET | 3981 | 2.985 |
10:17 ET | 29569 | 2.97 |
10:19 ET | 4298 | 2.97 |
10:21 ET | 10806 | 2.9699 |
10:24 ET | 19003 | 2.98 |
10:26 ET | 4900 | 2.975 |
10:28 ET | 400 | 2.9725 |
10:30 ET | 3702 | 2.98 |
10:32 ET | 4593 | 2.985 |
10:33 ET | 14670 | 3 |
10:35 ET | 2400 | 3.0091 |
10:37 ET | 10397 | 3.03 |
10:39 ET | 210 | 3.025 |
10:42 ET | 300 | 3.02 |
10:44 ET | 7853 | 3 |
10:46 ET | 3640 | 2.985 |
10:48 ET | 11006 | 2.99 |
10:50 ET | 5035 | 3.005 |
10:51 ET | 3269 | 2.99 |
10:53 ET | 2435 | 2.989 |
10:55 ET | 1500 | 2.9899 |
10:57 ET | 500 | 2.985 |
11:00 ET | 700 | 2.985 |
11:02 ET | 18103 | 3.005 |
11:04 ET | 35698 | 2.98 |
11:06 ET | 2918 | 2.98 |
11:08 ET | 4995 | 2.9866 |
11:09 ET | 730 | 2.9889 |
11:11 ET | 220 | 2.985 |
11:13 ET | 1016 | 2.985 |
11:15 ET | 988 | 2.985 |
11:18 ET | 5602 | 2.985 |
11:20 ET | 800 | 2.98 |
11:22 ET | 500 | 2.985 |
11:24 ET | 18188 | 2.98 |
11:26 ET | 7106 | 2.995 |
11:27 ET | 1672 | 2.9991 |
11:29 ET | 300 | 2.995 |
11:31 ET | 800 | 2.995 |
11:33 ET | 20092 | 2.9898 |
11:36 ET | 8994 | 2.995 |
11:38 ET | 9434 | 3.005 |
11:40 ET | 945 | 3.005 |
11:42 ET | 200 | 3.005 |
11:44 ET | 21812 | 2.975 |
11:45 ET | 500 | 2.9791 |
11:47 ET | 10495 | 2.985 |
11:49 ET | 250 | 2.9888 |
11:51 ET | 6851 | 2.98 |
11:54 ET | 800 | 2.98 |
11:56 ET | 1679 | 2.98 |
11:58 ET | 2715 | 2.975 |
12:00 ET | 67201 | 2.988 |
12:02 ET | 2011 | 2.975 |
12:03 ET | 15124 | 2.98 |
12:05 ET | 1415 | 2.975 |
12:07 ET | 3300 | 2.975 |
12:09 ET | 4927 | 2.975 |
12:12 ET | 36938 | 2.97 |
12:14 ET | 12697 | 2.9789 |
12:16 ET | 218 | 2.97 |
12:18 ET | 300 | 2.97 |
12:20 ET | 1650 | 2.965 |
12:21 ET | 12110 | 2.965 |
12:23 ET | 8869 | 2.98 |
12:25 ET | 272 | 2.975 |
12:27 ET | 632 | 2.975 |
12:30 ET | 900 | 2.975 |
12:32 ET | 400 | 2.975 |
12:34 ET | 7771 | 2.975 |
12:36 ET | 1151 | 2.97 |
12:38 ET | 800 | 2.96 |
12:39 ET | 3600 | 2.965 |
12:41 ET | 2374 | 2.965 |
12:43 ET | 2850 | 2.965 |
12:45 ET | 1133 | 2.9666 |
12:48 ET | 2443 | 2.965 |
12:50 ET | 2500 | 2.965 |
12:52 ET | 2923 | 2.9611 |
12:54 ET | 763 | 2.965 |
12:56 ET | 900 | 2.965 |
12:57 ET | 19701 | 2.955 |
12:59 ET | 4394 | 2.94 |
01:01 ET | 326 | 2.945 |
01:03 ET | 3100 | 2.9499 |
01:06 ET | 2305 | 2.945 |
01:08 ET | 500 | 2.945 |
01:10 ET | 23913 | 2.965 |
01:12 ET | 254 | 2.965 |
01:14 ET | 1175 | 2.97 |
01:15 ET | 1550 | 2.965 |
01:17 ET | 627 | 2.97 |
01:19 ET | 700 | 2.965 |
01:21 ET | 400 | 2.965 |
01:24 ET | 200 | 2.97 |
01:26 ET | 400 | 2.96 |
01:28 ET | 1494 | 2.965 |
01:30 ET | 750 | 2.9664 |
01:32 ET | 14836 | 2.94 |
01:33 ET | 2084 | 2.945 |
01:35 ET | 2213 | 2.945 |
01:37 ET | 832 | 2.94 |
01:39 ET | 8528 | 2.96 |
01:42 ET | 600 | 2.95 |
01:44 ET | 2287 | 2.955 |
01:46 ET | 804 | 2.955 |
01:48 ET | 2662 | 2.96 |
01:50 ET | 1500 | 2.95 |
01:51 ET | 400 | 2.96 |
01:53 ET | 400 | 2.96 |
01:55 ET | 600 | 2.955 |
01:57 ET | 4082 | 2.97 |
02:00 ET | 100 | 2.965 |
02:02 ET | 5918 | 2.965 |
02:04 ET | 200 | 2.965 |
02:06 ET | 2969 | 2.96 |
02:08 ET | 100 | 2.97 |
02:09 ET | 300 | 2.965 |
02:11 ET | 537 | 2.97 |
02:13 ET | 800 | 2.965 |
02:15 ET | 635 | 2.96 |
02:18 ET | 900 | 2.96 |
02:20 ET | 600 | 2.965 |
02:22 ET | 1150 | 2.96 |
02:24 ET | 200 | 2.965 |
02:26 ET | 1600 | 2.965 |
02:27 ET | 31436 | 2.975 |
02:29 ET | 200 | 2.975 |
02:31 ET | 2000 | 2.975 |
02:33 ET | 2480 | 2.9768 |
02:36 ET | 300 | 2.98 |
02:38 ET | 800 | 2.97 |
02:40 ET | 500 | 2.975 |
02:42 ET | 500 | 2.97 |
02:44 ET | 684 | 2.98 |
02:45 ET | 1000 | 2.975 |
02:47 ET | 900 | 2.975 |
02:49 ET | 10880 | 2.965 |
02:51 ET | 3228 | 2.965 |
02:54 ET | 1382 | 2.97 |
02:56 ET | 1000 | 2.96 |
02:58 ET | 1000 | 2.965 |
03:00 ET | 1116 | 2.965 |
03:02 ET | 6266 | 2.975 |
03:03 ET | 600 | 2.975 |
03:05 ET | 500 | 2.97 |
03:07 ET | 12600 | 2.975 |
03:09 ET | 900 | 2.975 |
03:12 ET | 3200 | 2.975 |
03:14 ET | 24825 | 2.976 |
03:16 ET | 1500 | 2.975 |
03:18 ET | 27511 | 2.975 |
03:20 ET | 200 | 2.975 |
03:21 ET | 25665 | 2.99 |
03:23 ET | 2341 | 2.985 |
03:25 ET | 600 | 2.985 |
03:27 ET | 400 | 2.99 |
03:30 ET | 900 | 2.99 |
03:32 ET | 900 | 2.985 |
03:34 ET | 17771 | 2.985 |
03:36 ET | 444 | 2.985 |
03:38 ET | 300 | 2.98 |
03:39 ET | 4000 | 2.985 |
03:41 ET | 33065 | 3 |
03:43 ET | 33785 | 2.985 |
03:45 ET | 1700 | 2.98 |
03:48 ET | 4289 | 2.985 |
03:50 ET | 3000 | 2.985 |
03:52 ET | 13036 | 2.985 |
03:54 ET | 3491 | 2.99 |
03:56 ET | 46795 | 2.975 |
03:57 ET | 25633 | 2.99 |
03:59 ET | 211565 | 2.98 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Nuvation Bio Inc | 736.6M | -9.5x | --- |
CARGO Therapeutics Inc | 725.8M | -5.4x | --- |
89Bio Inc | 747.7M | -3.8x | --- |
Hillevax Inc | 710.0M | -4.3x | --- |
Savara Inc | 707.0M | -11.2x | --- |
Perspective Therapeutics Inc | 706.8M | -6.5x | --- |
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $736.6M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 247.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.40 |
EPS | $-0.31 |
Book Value | $2.76 |
P/E Ratio | -9.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.